NovaBridge Biosciences shareholders approved the immediate removal of Xin Liu as a director at the September 8 AGM, where 121,294,288 shares were represented. The vote changes the board’s composition, while the represented shares accounted for approximately 44.8% of 270,740,383 outstanding shares and met the quorum requirement.
Key Highlights
- The meeting’s represented holdings included 6,078,571 ordinary shares and 115,215,717 shares through ADSs.
- Cao Sean Wuxiong exercised Options for 339,372 shares across two separate transactions.
- The AGM’s attendance satisfied the quorum rule in NovaBridge Biosciences’ amended and restated constitutional documents.
NovaBridge Biosciences (NASDAQ: NBP) shareholders approved the immediate removal of Ms. Xin Liu as a director at the annual general meeting, where approximately 44.8% of outstanding shares were represented. The resolution passed as an ordinary resolution.
AGM Representation and Voting Details
The meeting’s represented holdings included 6,078,571 ordinary shares and 115,215,717 shares held through American depositary shares. Attendance was measured against 270,740,383 shares outstanding as of the July 27, 2026 record date. The AGM took place on September 8, 2026, at NovaBridge Biosciences’ Shanghai office.
Immediate Effect Follows AGM Vote
Xin Liu’s removal became effective when shareholders passed the resolution. The quorum was established under the company’s governing documents, with approximately 44.8% of outstanding shares represented at the meeting. A separate transaction record identifies Cao Sean Wuxiong, the chief Business development officer, as having exercised options for 339,372 shares across two transactions.
FAQs
Q: What did NovaBridge Biosciences shareholders approve at the AGM?
A: Shareholders approved an ordinary resolution removing Xin Liu from her director position. The removal took effect immediately when the resolution passed at the annual general meeting.
Q: How many NovaBridge Biosciences shares were represented at the AGM?
A: Holders represented 121,294,288 shares at NovaBridge Biosciences’ annual general meeting. The total comprised 6,078,571 ordinary shares and 115,215,717 shares held through American depositary shares.
Q: What option transaction involved Cao Sean Wuxiong?
A: Cao Sean Wuxiong, NovaBridge Biosciences’ chief business development officer, exercised options for 339,372 shares. The exercise occurred across two separate transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.